|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
179 a.a.
|
 |
|
|
|
|
|
|
|
190 a.a.
|
 |
|
|
|
|
|
|
|
20 a.a.
|
 |
|
|
|
|
|
|
|
18 a.a.
|
 |
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system
|
 |
|
Title:
|
 |
Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two hla-dr2 alleles
|
|
Structure:
|
 |
Major histocompatibility complex alpha chain. Chain: a, d. Engineered: yes. Major histocompatibility complex beta chain. Chain: b, e. Engineered: yes. Myelin basic protein. Chain: c, f. Fragment: residues 86-105.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Other_details: homo sapiens. Synthetic: yes. Other_details: the peptide was chemically synthesized. The sequence of the peptide is naturally found in homo sapiens (human).
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
1.90Å
|
R-factor:
|
0.233
|
R-free:
|
0.267
|
|
|
Authors:
|
 |
H.Li,A.R.Mariuzza,Y.Li,R.Martin
|
Key ref:
|
 |
Y.Li
et al.
(2000).
Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
J Mol Biol,
304,
177-188.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
18-Sep-00
|
Release date:
|
27-Sep-00
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P01903
(DRA_HUMAN) -
HLA class II histocompatibility antigen, DR alpha chain from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
254 a.a.
179 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q30154
(DRB5_HUMAN) -
HLA class II histocompatibility antigen, DR beta 5 chain from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
266 a.a.
190 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
304:177-188
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
|
|
Y.Li,
H.Li,
R.Martin,
R.A.Mariuzza.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Susceptibility to multiple sclerosis (MS) is associated with certain MHC class
II haplotypes, in particular HLA-DR2. Two DR beta chains, DRB1*1501 and
DRB5*0101, are co-expressed in the HLA-DR2 haplotype, resulting in the formation
of two functional cell surface heterodimers, HLA-DR2a (DRA*0101, DRB5*0101) and
HLA-DR2b (DRA*0101, DRB1*1501). Both isotypes can present an immunodominant
peptide of myelin basic protein (MBP 84-102) to MBP-specific T cells from MS
patients. We have determined the crystal structure of HLA-DR2a complexed with
MBP 86-105 to 1.9 A resolution. A comparison of this structure with that of
HLA-DR2b complexed with MBP 85-99, reported previously, reveals that the peptide
register is shifted by three residues, such that the MBP peptide is bound in
strikingly different conformations by the two MHC molecules. This shift in
binding register is attributable to a large P1 pocket in DR2a, which
accommodates Phe92, in conjunction with a relatively shallow P4 pocket, which is
occupied by Ile95. In DR2b, by contrast, the small P1 pocket accommodates Val89,
while the deep P4 pocket is filled by Phe92. In both complexes, however, the
C-terminal half of the peptide is positioned higher in the binding groove than
in other MHC class II/peptide structures. As a result of the register shift,
different side-chains of the MBP peptide are displayed for interaction with T
cell receptors in the DR2a and DR2b complexes. These results demonstrate that
MHC molecules can impose different alignments and conformations on the same
bound peptide as a consequence of topological differences in their
peptide-binding sites, thereby creating distinct T cell epitopes.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. (a) Electron density for the bound peptide in the HLA-DR2a/MBP 86-105 complex. The Fo
-
Fc omit map
at 1.9 Å resolution is contoured at 2s. (b) Superposition of the MBP 86-105 peptide (red) bound by HLA-DR2a onto
the MBP 85-99 peptide (green) bound by HLA-DR2b (Smith et al., 1998). (c) Alignment of MBP 86-105 and MBP 85-
99 according to their registers in the peptide-binding grooves of HLA-DR2a and HLA-DR2b, respectively.
|
 |
Figure 3.
Figure 3. (a) Superposition of peptides bound to
human MHC class II molecules. The MBP 86-105 pep-
tide bound to HLA-DR2a is red and the MBP 85-99 pep-
tide bound to HLA-DR2b (Smith et al., 1998) is green. In
yellow are peptides bound to other HLA-DR molecules:
DR1 (Stern et al., 1994), DR3 (Ghosh et al., 1995) and
DR4 (Dessen et al., 1997). HLA-DR2a is shown in gray.
The peptide backbones superpose well from P-2 to P4,
but display considerable divergence beginning at P6. In
particular, the C-terminal portions of the MBP peptides
presented by DR2a and DR2b are positioned higher in
the binding groove than the C-terminal portions of pep-
tides presented by DR1, DR3, or DR4. (b) Confor-
mations of Trp61b in HLA-DR2a and HLA-DR3. In red
are the MBP peptide bound to HLA-DR2a and the side-
chains of residues Trp61b and Leu38b of this DR. In yel-
low are CLIP peptide bound to HLA-DR3 (Ghosh et al.,
1995) and the side-chains of Trp61b and Val38b. HLA-
DR2a and HLA-DR3 are gray and blue, respectively.
Superpositions were done using the a1 and b1 domains
of the DR molecules.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2000,
304,
177-188)
copyright 2000.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
B.E.Hansen,
C.H.Nielsen,
H.O.Madsen,
L.P.Ryder,
B.K.Jakobsen,
and
A.Svejgaard
(2011).
The HLA-DP2 protein binds the immunodominant epitope from myelin basic protein, MBP85-99, with high affinity.
|
| |
Tissue Antigens,
77,
229-234.
|
 |
|
|
|
|
 |
J.Huan,
R.Meza-Romero,
J.L.Mooney,
A.A.Vandenbark,
H.Offner,
and
G.G.Burrows
(2011).
Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease.
|
| |
Mucosal Immunol,
4,
112-120.
|
 |
|
|
|
|
 |
S.O.Ryan,
J.A.Bonomo,
F.Zhao,
and
B.A.Cobb
(2011).
MHCII glycosylation modulates Bacteroides fragilis carbohydrate antigen presentation.
|
| |
J Exp Med,
208,
1041-1053.
|
 |
|
|
|
|
 |
Zaheer-ul-Haq,
and
W.Khan
(2011).
Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs.
|
| |
J Comput Aided Mol Des,
25,
81.
|
 |
|
|
|
|
 |
C.T.Spencer,
P.Gilchuk,
S.M.Dragovic,
and
S.Joyce
(2010).
Minor histocompatibility antigens: presentation principles, recognition logic and the potential for a healing hand.
|
| |
Curr Opin Organ Transplant,
15,
512-525.
|
 |
|
|
|
|
 |
K.Yeturu,
T.Utriainen,
G.J.Kemp,
and
N.Chandra
(2010).
An automated framework for understanding structural variations in the binding grooves of MHC class II molecules.
|
| |
BMC Bioinformatics,
11,
S55.
|
 |
|
|
|
|
 |
C.S.Parry,
and
B.R.Brooks
(2008).
A new model defines the minimal set of polymorphism in HLA-DQ and -DR that determines susceptibility and resistance to autoimmune diabetes.
|
| |
Biol Direct,
3,
42.
|
 |
|
|
|
|
 |
C.S.Parry
(2008).
Flanking p10 contribution and sequence bias in matrix based epitope prediction: revisiting the assumption of independent binding pockets.
|
| |
BMC Struct Biol,
8,
44.
|
 |
|
|
|
|
 |
R.Etzensperger,
R.M.McMahon,
E.Y.Jones,
and
L.Fugger
(2008).
Dissection of the multiple sclerosis associated DR2 haplotype.
|
| |
J Autoimmun,
31,
201-207.
|
 |
|
|
|
|
 |
S.S.Vollers,
and
L.J.Stern
(2008).
Class II major histocompatibility complex tetramer staining: progress, problems, and prospects.
|
| |
Immunology,
123,
305-313.
|
 |
|
|
|
|
 |
B.E.Hansen,
A.H.Rasmussen,
B.K.Jakobsen,
L.P.Ryder,
and
A.Svejgaard
(2007).
Extraordinary cross-reactivity of an autoimmune T-cell receptor recognizing specific peptides both on autologous and on allogeneic HLA class II molecules.
|
| |
Tissue Antigens,
70,
42-52.
|
 |
|
|
|
|
 |
G.P.Bondinas,
A.K.Moustakas,
and
G.K.Papadopoulos
(2007).
The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function.
|
| |
Immunogenetics,
59,
539-553.
|
 |
|
|
|
|
 |
E.Y.Jones,
L.Fugger,
J.L.Strominger,
and
C.Siebold
(2006).
MHC class II proteins and disease: a structural perspective.
|
| |
Nat Rev Immunol,
6,
271-282.
|
 |
|
|
|
|
 |
J.C.Tong,
G.L.Zhang,
T.W.Tan,
J.T.August,
V.Brusic,
and
S.Ranganathan
(2006).
Prediction of HLA-DQ3.2beta ligands: evidence of multiple registers in class II binding peptides.
|
| |
Bioinformatics,
22,
1232-1238.
|
 |
|
|
|
|
 |
M.Sospedra,
P.A.Muraro,
I.Stefanová,
Y.Zhao,
K.Chung,
Y.Li,
M.Giulianotti,
R.Simon,
R.Mariuzza,
C.Pinilla,
and
R.Martin
(2006).
Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype.
|
| |
J Immunol,
176,
1951-1961.
|
 |
|
|
|
|
 |
S.T.Chang,
D.Ghosh,
D.E.Kirschner,
and
J.J.Linderman
(2006).
Peptide length-based prediction of peptide-MHC class II binding.
|
| |
Bioinformatics,
22,
2761-2767.
|
 |
|
|
|
|
 |
Y.Li,
Y.Huang,
J.Lue,
J.A.Quandt,
R.Martin,
and
R.A.Mariuzza
(2005).
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule.
|
| |
EMBO J,
24,
2968-2979.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.G.Tzakos,
P.Fuchs,
N.A.van Nuland,
A.Troganis,
T.Tselios,
S.Deraos,
J.Matsoukas,
I.P.Gerothanassis,
and
A.M.Bonvin
(2004).
NMR and molecular dynamics studies of an autoimmune myelin basic protein peptide and its antagonist: structural implications for the MHC II (I-Au)-peptide complex from docking calculations.
|
| |
Eur J Biochem,
271,
3399-3413.
|
 |
|
|
|
|
 |
G.J.Carven,
S.Chitta,
I.Hilgert,
M.M.Rushe,
R.F.Baggio,
M.Palmer,
J.E.Arenas,
J.L.Strominger,
V.Horejsi,
L.Santambrogio,
and
L.J.Stern
(2004).
Monoclonal antibodies specific for the empty conformation of HLA-DR1 reveal aspects of the conformational change associated with peptide binding.
|
| |
J Biol Chem,
279,
16561-16570.
|
 |
|
|
|
|
 |
I.R.Bates,
J.B.Feix,
J.M.Boggs,
and
G.Harauz
(2004).
An immunodominant epitope of myelin basic protein is an amphipathic alpha-helix.
|
| |
J Biol Chem,
279,
5757-5764.
|
 |
|
|
|
|
 |
J.W.Gregersen,
S.Holmes,
and
L.Fugger
(2004).
Humanized animal models for autoimmune diseases.
|
| |
Tissue Antigens,
63,
383-394.
|
 |
|
|
|
|
 |
K.Petersson,
G.Forsberg,
and
B.Walse
(2004).
Interplay between superantigens and immunoreceptors.
|
| |
Scand J Immunol,
59,
345-355.
|
 |
|
|
|
|
 |
M.H.Sung,
and
R.Simon
(2004).
Genomewide conserved epitope profiles of HIV-1 predicted by biophysical properties of MHC binding peptides.
|
| |
J Comput Biol,
11,
125-145.
|
 |
|
|
|
|
 |
R.C.Hillig,
M.Hülsmeyer,
W.Saenger,
K.Welfle,
R.Misselwitz,
H.Welfle,
C.Kozerski,
A.Volz,
B.Uchanska-Ziegler,
and
A.Ziegler
(2004).
Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association.
|
| |
J Biol Chem,
279,
652-663.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.P.Finn,
R.E.Jones,
C.Rich,
R.Dahan,
J.Link,
C.S.David,
Y.K.Chou,
H.Offner,
and
A.A.Vandenbark
(2004).
HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes.
|
| |
J Neurosci Res,
78,
100-114.
|
 |
|
|
|
|
 |
Z.Zavala-Ruiz,
I.Strug,
B.D.Walker,
P.J.Norris,
and
L.J.Stern
(2004).
A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition.
|
| |
Proc Natl Acad Sci U S A,
101,
13279-13284.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Z.Zavala-Ruiz,
I.Strug,
M.W.Anderson,
J.Gorski,
and
L.J.Stern
(2004).
A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins.
|
| |
Chem Biol,
11,
1395-1402.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.W.Purcell,
W.Zeng,
N.A.Mifsud,
L.K.Ely,
W.A.Macdonald,
and
D.C.Jackson
(2003).
Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.
|
| |
J Pept Sci,
9,
255-281.
|
 |
|
|
|
|
 |
J.A.Snyder,
A.Weston,
S.S.Tinkle,
and
E.Demchuk
(2003).
Electrostatic potential on human leukocyte antigen: implications for putative mechanism of chronic beryllium disease.
|
| |
Environ Health Perspect,
111,
1827-1834.
|
 |
|
|
|
|
 |
Z.Zavala-Ruiz,
E.J.Sundberg,
J.D.Stone,
D.B.DeOliveira,
I.C.Chan,
J.Svendsen,
R.A.Mariuzza,
and
L.J.Stern
(2003).
Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1.
|
| |
J Biol Chem,
278,
44904-44912.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.A.Daubenberger,
B.Nickel,
C.Ciatto,
M.G.Grütter,
F.Pöltl-Frank,
L.Rossi,
U.Siegler,
J.Robinson,
O.Kashala,
M.E.Patarroyo,
and
G.Pluschke
(2002).
Amino acid dimorphism and parasite immune evasion: cellular immune responses to a promiscuous epitope of Plasmodium falciparum merozoite surface protein 1 displaying dimorphic amino acid polymorphism are highly constrained.
|
| |
Eur J Immunol,
32,
3667-3677.
|
 |
|
|
|
|
 |
E.J.Sundberg,
Y.Li,
and
R.A.Mariuzza
(2002).
So many ways of getting in the way: diversity in the molecular architecture of superantigen-dependent T-cell signaling complexes.
|
| |
Curr Opin Immunol,
14,
36-44.
|
 |
|
|
|
|
 |
J.S.Murray,
S.D.Fois,
T.Schountz,
S.R.Ford,
M.D.Tawde,
J.C.Brown,
and
T.J.Siahaan
(2002).
Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions.
|
| |
J Pept Res,
59,
115-122.
|
 |
|
|
|
|
 |
M.H.Sung,
Y.Zhao,
R.Martin,
and
R.Simon
(2002).
T-cell epitope prediction with combinatorial peptide libraries.
|
| |
J Comput Biol,
9,
527-539.
|
 |
|
|
|
|
 |
P.E.Adrian,
G.Rajaseger,
V.S.Mathura,
M.K.Sakharkar,
and
P.Kangueane
(2002).
Types of inter-atomic interactions at the MHC-peptide interface: identifying commonality from accumulated data.
|
| |
BMC Struct Biol,
2,
2.
|
 |
|
|
|
|
 |
T.D.Lockey,
S.Surman,
S.Brown,
K.S.Slobod,
C.Coleclough,
P.C.Doherty,
and
J.L.Hurwitz
(2002).
A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty?
|
| |
AIDS Res Hum Retroviruses,
18,
1141-1144.
|
 |
|
|
|
|
 |
X.Liu,
S.Dai,
F.Crawford,
R.Fruge,
P.Marrack,
and
J.Kappler
(2002).
Alternate interactions define the binding of peptides to the MHC molecule IA(b).
|
| |
Proc Natl Acad Sci U S A,
99,
8820-8825.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Petersson,
M.Håkansson,
H.Nilsson,
G.Forsberg,
L.A.Svensson,
A.Liljas,
and
B.Walse
(2001).
Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence.
|
| |
EMBO J,
20,
3306-3312.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.R.Rose
(2001).
Infection, mimics, and autoimmune disease.
|
| |
J Clin Invest,
107,
943-944.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
| |